Myomectomy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Myomectomy market size in 2026 is estimated at USD 742.3 million, growing from 2025 value of USD 0.69 billion with 2031 projections showing USD 1.07 billion, growing at 7.58% CAGR over 2026-2031. This report is Segmented by Procedure Type (Abdominal Myomectomy, Laparoscopic Myomectomy, Hysteroscopic, and More), Product (Laparoscopic Power Morcellators, Tissue Removal Systems, Energy & Sealing Devices, and More), End User (Hospitals & Clinics, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Myomectomy Market Trends and Insights

Growing Incidence of Uterine Fibroids Among Reproductive-Age Women

Fibroids now affect up to 70-80% of women by age 50, but the burden is most acute for those aged 25-44, the prime fertility window. Global surveillance recorded 9.6 million newly diagnosed cases in 2024.African ancestry doubles to triple the risk, compelling healthcare systems to prioritize uterus-sparing options. United States payers already spend USD 34.4 billion annually on fibroid care, reinforcing surgical demand. As delayed childbirth trends intersect with higher fibroid prevalence, the myomectomy market continues to expand.

Rising Adoption of Minimally Invasive & Robotic-Assisted Surgeries

From 2013 to 2019, robotic procedures grew from 16.3% to 30.3% of total U.S. surgeries; gynecology accounted for a substantial share. The da Vinci 5 platform adds tactile feedback that lowers tissue trauma by 43%, addressing concerns over knot-tying accuracy and ergonomic strain. Nonetheless, capital outlays exceed USD 2 million per unit, and surgeons need 20-40 cases to achieve competence, slowing uptake in resource-constrained settings. Technical advantages, however, are gradually overriding cost hesitancy, feeding double-digit segment growth.

High Cost of Advanced Laparoscopic & Robotic Systems

Hospitals face USD 2 million up-front costs plus maintenance when adopting robotic platforms, stretching capital budgets. Even with volume sharing, reaching economic break-even demands 150-200 annual cases. Emerging markets, where reimbursement is nascent, delay procurement and rely on conventional laparoscopy, restricting global diffusion.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Fertility-Preservation Preference Delaying Hysterectomy
• Emergence of Outpatient Reimbursement Models for ASC Procedures
• Safety Concerns over Morcellation-Related Malignancy Spread

Segment Analysis

Laparoscopic surgery maintained a 33.20% myomectomy market share in 2025, thanks to surgeon familiarity and broad availability. Robotic-assisted procedures, advancing at 9.46% CAGR, are eroding this lead by offering 3-dimensional vision and articulated instruments that simplify suturing in confined pelvic spaces. Abdominal open myomectomy persists for very large or numerous fibroids, but steadily declines as minimally invasive proficiency climbs. Hysteroscopic resection holds traction for submucosal fibroids, aided by improved single-use shavers that lessen fluid overload risk. Vaginal approaches remain niche, reserved for select posterior wall tumors.

Technological progress reinforces the shift: force-feedback sensors in next-generation robots decrease unintended tissue strain, while single-port laparoscopy enhances cosmesis for select cases. Training initiatives from professional societies are accelerating skilled labor supply, which in turn widens patient access to minimally invasive care across tertiary centers. The combined impact cements robots as a future mainstream modality within the myomectomy market.

Complete Report Scope:

• By Procedure Type
  • Abdominal (Open) Myomectomy
  • Laparoscopic Myomectomy
  • Hysteroscopic Myomectomy
  • Robotic-Assisted Myomectomy
  • Vaginal Myomectomy
• By Product
  • Laparoscopic Power Morcellators
  • Tissue Removal Systems (Hysteroscopic Morcellators)
  • Energy & Sealing Devices
  • Suturing & Closure Devices
  • Imaging & Navigation Systems
  • Ancillary Instruments & Consumables
• By End User
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Specialty Fertility Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the myomectomy market size at 31.40% share in 2025 due to robust insurance coverage and the world’s highest concentration of robotic systems, over 6,000 installed units. Early adoption of FDA-cleared containment devices sustains minimally invasive momentum despite heightened morcellation scrutiny. Yet access inequity persists; Black women are 30% less likely than their counterparts to receive laparoscopic myomectomy even when clinically eligible. Federal and state programs are funding surgeon-training scholarships to narrow this gap.

Asia Pacific is forecast to post the fastest regional CAGR of 8.52% to 2031, propelled by national health-insurance expansions, rising middle-class expectations, and localized medical-device manufacturing. China’s domestic robot makers are filing for National Medical Products Administration approvals, aiming to lower unit costs by up to 35% relative to imported systems. Japan and South Korea maintain procedure volumes comparable to Western peers, while India and Indonesia prioritize capacity building with laparoscopic platforms first who.int. Professional exchanges, online simulation modules, and traveling fellowships are lifting surgical skill levels.

Europe retains steady growth under the harmonized Medical Device Regulation that guarantees high safety standards. Public health systems reimburse minimally invasive gynecology widely, though austerity policies limit robotic capital budgets in certain markets.

Middle East & Africa are nascent but promising; flagship hospitals in Saudi Arabia and South Africa have adopted robotic programs, often via public-private partnerships. Latin America shows moderate expansion; in Mexico’s public sector only 16.5% of fibroid procedures are laparoscopic, yet private institutions in Brazil have introduced comprehensive myomectomy centers that double as regional training hubs.

List of Companies Covered in this Report:

• Medtronic
• Stryker
• Intuitive Surgical
• Johnson & Johnson
• Karl Storz
• Olympus
• B. Braun
• Conmed
• Hologic
• The Cooper Companies
• INSIGHTEC
• Gynesonics Inc.
• Minerva Surgical
• Richard Wolf
• Boston Scientific
• Smiths Group
• Zimmer Biomet
• Lumenis
• Canyon Medical Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support